|
|
|
This collection features a range of resources on key topics in early-phase clinical development, reflecting current challenges and considerations in the field.
|
|
|
|
A timely conversation on how to structure early-phase trials to address population variability and key factors influencing safe drug administration — both critical to developing a comprehensive, equitable drug development plan that reflects diverse patient subtypes.
|
|
|
|
Incorporating proof-of-concept arms into a Phase I protocol provides earlier access to critical data, supporting more informed go/no-go decisions. This approach can accelerate development, optimize resources, reduce costs, and keep timelines on track.
|
|
|
|
Did you know that conducting your trials in Canada can accelerate early-phase clinical research by six to nine weeks? Discover the unique advantages of running early-phase studies on novel compounds in Canada versus other regions.
|
|
|
|
From preclinical models and bioanalytical assays to clinical study design and manufacturing strategies, this issue of The Altascientist features exclusive case studies and expert insights on the complexities of GLP-1 RA development.
|
|
|
|
Here, we present an overview of the FDA's guidance and key considerations for the clinical development of psychedelics — including assessing abuse potential using the Eight Factor Analysis (8FA), and optimizing trials through effective blinding, active control selection, and the strategic use of facilitators.
|
|
|
|
In this short documentary, Altasciences leads the conversation on innovation in a traditionally slow-moving industry, examining the challenges of conventional CRO-sponsor relationships and presenting a new, alternative model.
|
|
|
|
|
Altasciences provides deep expertise in all clinical pharmacology studies required for successful regulatory submission across a wide range of therapeutic areas.
View the complete resource library.
Contact an Altasciences expert to learn more about their comprehensive clinical solution.
|
|
|